BioMarin Pharmaceutical

BMRNintermediary

BioMarin Pharmaceutical is a leader in rare-disease therapeutics with a portfolio of enzyme replacement therapies and the breakthrough growth drug Voxzogo for achondroplasia. Its Roctavian gene therapy for hemophilia A represents a one-time curative approach.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($2.8B)

静态数据（加载实时财务…）

Enzyme Replacement Therapies (45%)

Voxzogo (30%)

Roctavian & Other (15%)

Royalties & Collaborations (10%)

业务板块构成与主要客户

产品详情

Voxzogo (vosoritide)30%

C-type natriuretic peptide analog for achondroplasia in children

Roctavian (AAV gene therapy)10%

Gene therapy for severe hemophilia A

Enzyme Replacement Therapies45%

Naglazyme, Vimizim, and Palynziq for lysosomal storage disorders and PKU

供应链关系

竞争对手

Regeneron Pharmaceuticals

Rare disease biologics

影响: Limited overlap in rare disease

Pfizer Inc.

Gene therapy platforms

影响: Competing in gene therapy

Novo Nordisk

Rare blood disorders

影响: Competing in hemophilia

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 BioMarin Pharmaceutical 的 AI 供应链分析。

企业信息

总部

San Rafael, California, USA

成立时间

1997

员工人数

4,200+

官网

biomarin.com

行业概况 — 제약 / 바이오

行业新闻